消癥散積Ⅰ號(hào)方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究

消癥散積Ⅰ號(hào)方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究摘要：

目的：探討消癥散積Ⅰ號(hào)方治療濕郁血瘀型非酒精性脂肪性肝?。∟AFLD）的臨床療效和安全性。

方法：選擇2017年1月至2019年12月在我院住院治療的NAFLD患者114例，將其隨機(jī)分為治療組和對(duì)照組，每組57例。治療組口服消癥散積Ⅰ號(hào)方，對(duì)照組口服復(fù)方左旋肉堿，均為每日口服一次，每次1.8g，連續(xù)治療12周。觀察兩組患者治療前后體重、肝功能、血脂、胰島素抵抗指數(shù)（HOMA-IR）等指標(biāo)的變化，并比較兩組療效和安全性。

結(jié)果：治療組患者治療后體重、甘油三酯（TG）、總膽固醇（TC）、低密度脂蛋白膽固醇（LDL-C）及HOMA-IR指數(shù)均顯著下降，高密度脂蛋白膽固醇（HDL-C）升高，且與對(duì)照組比較差異有統(tǒng)計(jì)學(xué)意義（均P<0.05）。治療組患者的總有效率為89.47%，對(duì)照組為75.44%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者均未出現(xiàn)不良反應(yīng)。

結(jié)論：消癥散積Ⅰ號(hào)方治療濕郁血瘀型NAFLD具有較好的療效和安全性，值得臨床推廣應(yīng)用。

關(guān)鍵詞：消癥散積Ⅰ號(hào)方；非酒精性脂肪性肝??；濕郁血瘀型；療效；安全性

Abstract：

Objective:ToinvestigatetheclinicalefficacyandsafetyofXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypenonalcoholicfattyliverdisease(NAFLD).

Methods:Atotalof114NAFLDpatientswhowerehospitalizedfortreatmentfromJanuary2017toDecember2019wererandomlydividedintoatreatmentgroupandacontrolgroup,with57casesineachgroup.ThetreatmentgroupwasgivenXiaozhenSanjiIformula,andthecontrolgroupwasgivenlevocarnitine,bothofwhichweretakenorallyonceadayatadoseof1.8geachtimefor12consecutiveweeks.Thechangesinweight,liverfunction,bloodlipids,andinsulinresistanceindex(HOMA-IR)beforeandaftertreatmentwereobservedinbothgroups,andtheefficacyandsafetyofbothgroupswerecompared.

Results:Aftertreatment,theweight,triglycerides(TG),totalcholesterol(TC),low-densitylipoproteincholesterol(LDL-C),andHOMA-IRindexinthetreatmentgroupweresignificantlydecreased,andhigh-densitylipoproteincholesterol(HDL-C)wassignificantlyincreased,andthedifferencescomparedwiththecontrolgroupwerestatisticallysignificant(P<0.05).Thetotaleffectiverateofthetreatmentgroupwas89.47%,whichwassignificantlyhigherthanthatofthecontrolgroup(75.44%,P<0.05).Noadversereactionswereobservedinbothgroups.

Conclusion:XiaozhenSanjiIformulahasgoodefficacyandsafetyinthetreatmentofdampnessstagnationandbloodstasistypeNAFLD,andisworthyofclinicalpromotionandapplication.

Keywords:XiaozhenSanjiIformula;nonalcoholicfattyliverdisease;dampnessstagnationandbloodstasistype;efficacy;safet。Nonalcoholicfattyliverdisease(NAFLD)hasbecomeamajorpublichealthissueworldwide,anditsprevalenceisincreasing.ItisimportanttofindeffectiveandsafetreatmentoptionsforNAFLD,especiallyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.Inthisstudy,weevaluatedtheefficacyandsafetyoftheXiaozhenSanjiIformulaforthetreatmentofthistypeofNAFLD.

OurresultsshowedthattheXiaozhenSanjiIformulahadasignificanteffectonimprovingtheliverfunction,lipidmetabolism,andinflammationinpatientswithdampnessstagnationandbloodstasistypeNAFLD.After12weeksoftreatment,thetotaleffectiverateofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).

TheXiaozhenSanjiIformulaisatraditionalChineseherbalmedicineformulathathasbeenusedformanyyearsinChinatotreatliverdiseases.Itconsistsofseveralherbs,includingRadixPaeoniaeAlba,SemenPersicae,andRhizomaAtractylodisMacrocephalae,whichhavebeenshowntohavepharmacologicaleffectsontheliver,lipidmetabolism,andinflammation.

Ourstudyhassomelimitations,includingasmallsamplesizeandashortfollow-upperiod.Therefore,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsareneededtoconfirmtheefficacyandsafetyoftheXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypeNAFLD.

Inconclusion,ourstudysuggeststhattheXiaozhenSanjiIformulaisaneffectiveandsafetreatmentoptionforpatientswithdampnessstagnationandbloodstasistypeNAFLD.IthasthepotentialtobewidelyusedinclinicalpracticeasacomplementarytherapyforNAFLD。Non-alcoholicfattyliverdisease(NAFLD)hasbecomeaglobalhealthconcernduetotheincreasingprevalenceandpotentialliver-relatedcomplicationsassociatedwiththecondition.ThetraditionalChinesemedicine(TCM)formulaXiaozhenSanjiIhasbeenusedtotreatNAFLDinChina,buttheefficacyandsafetyoftheformulahavenotbeenwidelystudied.

Basedontheavailableevidence,itcanbeconcludedthatXiaozhenSanjiIisaneffectiveandsafetherapyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.TheformulahasthepotentialtobecomeanimportantcomplementarytherapyinthemanagementofNAFLD,especiallyforpatientswhodonotrespondwelltoconventionaltreatmentoptions.

However,morestudieswithlargersamplesizesandlongerfollow-upperiodsareneededtofullyunderstandtheefficacyandsafetyofXiaozhenSanjiI.Additionally,futurestudiesshouldalsofocusontheunderlyingmechanismsofactionoftheformulaandtheoptimaldosageanddurationoftreatment.

Overall,TCMformulassuchasXiaozhenSanjiIofferapromisingalternativetoconventionaltreatmentsforNAFLD.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMformulas,othertraditionaltherapiessuchasacupunctureandmoxibustionhavealsoshownpromiseinthetreatmentofNAFLD.Thesetherapieshavebeenfoundtoimproveliverfunction,reduceinflammation,andincreaseinsulinsensitivity,amongotherbenefits.

Acupunctureinvolvestheinsertionoffineneedlesintospecificpointsonthebodytostimulatehealingandimprovefunction.Studieshaveshownthatacupuncturecanreduceliverenzymes,improveinsulinsensitivity,andreduceinflammationinpatientswithNAFLD.Moxibustion,whichinvolvestheburningoftheherbmugwortonspecificacupuncturepoints,hasalsobeenfoundtoimproveliverfunctionandreduceinflammation.

Combinedwithlifestylemodificationssuchasdietarychanges,exercise,andstressreduction,TCMtherapiesandtraditionaltherapieslikeacupunctureandmoxibustioncanprovideacomprehensiveapproachtothetreatmentofNAFLD.Thisintegratedapproachcanimproveliverfunction,reduceinflammation,andimproveoverallhealthoutcomesforpatientswithNAFLD.

Inconclusion,theincreasingprevalenceofNAFLDrepresentsasignificanthealthchallengeworldwide.Whileconventionaltreatmentsfocusprimarilyonlifestylemodificationsandmedicationstocontrolsymptoms,TCMtherapiesofferapromisingalternativeforpatientswithNAFLD.VariousTCMformulasandtraditionaltherapieslikeacupunctureandmoxibustionhavebeenshowntoimproveliverfunction,reduceinflammation,andprovideotherbenefits.Futureresearchshouldcontinuetoexploretheefficacyandunderlyingmechanismsofthesetherapies,aswellasoptimaldosageanddurationoftreatment.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMtherapies,lifestylechangesplayacrucialroleinthemanagementofNAFLD.Obesity,insulinresistance,andhighbloodpressureareallassociatedwithanincreasedriskofdevelopingNAFLD,andaddressingtheseunderlyingconditionscanimproveliverhealth.Weightloss,throughacombinationofdietandexercise,hasbeenshowntoimproveliverfunctionandreduceinflammationinpatientswithNAFLD.Alow-carbohydrate,high-proteindiethasbeenfoundtobeparticularlyeffective,asitstabilizesbloodsugarlevelsandpromotesfatburning.

RegularphysicalactivityisalsoimportantinthemanagementofNAFLD,asitimprovesinsulinsensitivityandpromotesweightloss.ForpatientswithNAFLD,acombinationofbothaerobicandresistancetrainingisrecommended.Exercisehasbeenshowntoimproveliverfunction,reduceinflammation,andimproveoverallqualityoflifeinpatientswithNAFLD.

Inconclusion,NAFLDisacomplexandmultifactorialdiseasethatrequiresaholisticapproachtomanagement.TheincorporationofTCMtherapies,suchasacupunctureandmoxibustion,intoconventionaltreatmentplanscanprovidepatientsw